Strategic Partnerships C2N has established international partnerships in Australia and Brazil to bring PrecivityAD and related brain health biomarkers to market. This indicates strong partner-led channels for expansion and potential collaboration opportunities with regional distributors, clinics, and health networks to scale sales.

Clinical Adoption PrecivityAD is a mass spectrometry based blood test offered in a CLIA-certified lab and is orderable by healthcare providers to aid in evaluating brain amyloid plaques. This suggests a clear value proposition for neurology practices, memory clinics, and primary care networks focusing on dementia screening and brain health assessment.

Regulatory Endorsements The product has FDA Breakthrough Device Designation and CE Mark, signaling strong regulatory validation that can be leveraged in sales conversations with hospitals, payers, and clinical networks seeking innovative, approved diagnostics with potential reimbursement pathways.

Expansion Opportunities Recent launches of PrecivityAD2 for patients aged 60+ indicate a move to broaden the target population and use cases. This presents cross-sell opportunities within existing customers and appeal to clinics serving older adult cohorts, geriatric practices, and memory care centers.

Revenue Growth Potential With substantial revenue and multi-million funding alongside international partnerships, there is a credible growth story to fuel business development pitches to strategic investors, health systems, and payer organizations interested in cost-effective brain health testing and early Alzheimer’s disease assessment.